Evidence map›Paper›PMID 41852701›Full record

ArticleLiver cancer2026

Liver Stiffness Measured by Vibration-Controlled Transient Elastography Predicts Hepatic Decompensation in Patients with Hepatocellular Carcinoma Receiving Systemic Treatments.

Jaejun Lee, Hyun Yang, Si Hyun Bae, Hee Sun Cho, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Keungmo Yang, Heechul Nam, Chang Wook Kim and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jaejun LeeDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Hyun YangDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Si Hyun BaeDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Hee Sun ChoDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Pil Soo SungDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Jeong Won JangDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Seung Kew YoonDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Keungmo YangDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Heechul NamDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Chang Wook KimDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Hae Lim LeeDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Hee Yeon KimDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Sung Won LeeDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Ahlim LeeDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Do Seon SongDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Seok Hwan KimDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Myung Jun SongDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Soon Kyu LeeDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Jung Hyun KwonDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Soon Woo NamDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Ji Won HanDepartment of Biomedicine and Health Sciences, College of Medicine, The Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Hepatic decompensation (HD) following systemic treatment, including atezolizumab + bevacizumab (Atezo/Bev) and tyrosine kinase inhibitors (TKIs), is a critical prognostic event in advanced hepatocellular carcinoma (HCC). This study aimed to evaluate the predictive utility of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) for HD incidence post-treatment. Methods: This multicenter study included 396 HCC patients who received systemic therapy (Atezo/Bev or TKIs) and underwent VCTE prior to treatment at seven university-affiliated hospitals. Clinical outcomes including HD independent of tumor progression, variceal bleeding (VB), overall survival (OS), and progression-free survival (PFS) were assessed. A 25 kPa LSM threshold, based on Baveno VII criteria, stratified patients into high and low LSM groups. Results: Of the 396 patients, 176 received Atezo/Bev, while 45 and 175 received lenvatinib and sorafenib, respectively. Treatment distribution was similar between high and low LSM groups ( Conclusion: LSM by VCTE predicts HD following systemic treatment in advanced HCC. In patients with high LSM, Atezo/Bev increases HD risk, warranting careful treatment selection.

Indexed as

Atezolizumab and bevacizumabHepatic decompensationHepatocellular carcinomaLiver stiffness measurementTransient elastography

Identifiers

PMID41852701
PMCPMC12995380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.